Brilinta News
Most Popular Brilinta Story
Brilinta - FDA's Top 10 Blockuster Decisions
Drug: Brilinta (ticagrelor)Company: AstraZenecaPDUFA date: December 16, 2010Market potential: $2 billion-$4 billion AstraZeneca needs this win, and the advisory panel was inclined to give it to them. Read more...
Latest Headlines
- June 28, 2011
- December 20, 2010
- December 17, 2010
- October 11, 2010
- September 24, 2010
- September 15, 2010
- September 10, 2010
- November 19, 2009
- November 18, 2009
- November 17, 2009
- August 31, 2009
- June 4, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
